Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

Shares of EVOK stock opened at $4.22 on Friday. The firm has a market capitalization of $6.29 million, a price-to-earnings ratio of -0.38 and a beta of 0.16. The company has a 50 day moving average price of $5.08 and a 200 day moving average price of $5.38. Evoke Pharma has a one year low of $3.54 and a one year high of $16.44.

Institutional Investors Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. bought a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma as of its most recent filing with the SEC.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.